NICE rejects Dupixent for atopic dermatitis in a preliminary decision. - Sanofi.
The National Institute for Health and Care Excellence (NICE) has issued draft guidance that does not recommend Dupixent (dupilumab), within its marketing authorisation, for the treatment of moderate-to-severe atopic dermatitis in adults when systemic therapy is suitable. This appraisal consultation document (ACD) is not NICE�s final decision on dupilumab.
The draft guidance noted that the clinical evidence shows that dupilumab is effective at treating moderate-to-severe atopic dermatitis following failure (or contraindication) of topical therapies and systemic immunosuppressant agents. However, NICE felt there was uncertainty about cost-effectiveness estimates for dupilumab, which were higher than those NICE normally considers an acceptable use of NHS resources.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.